Franklin Templeton has announced a definitive agreement to acquire a majority stake in Apera Asset Management, marking a strategic expansion of its European private credit capabilities. The acquisition of Apera, a firm managing over €5 billion in assets, supports Franklin Templeton’s long-term strategy to broaden its global alternatives platform.
Acquisition Enhances European Private Credit Reach
Through this transaction, Franklin Templeton will significantly increase its alternative credit assets under management (AUM) to $87 billion, with total pro-forma alternative AUM rising to $260 billion as of April 30, 2025. Apera’s integration will complement existing affiliates such as Benefit Street Partners in the U.S. and Alcentra in Europe, adding geographic depth and further diversifying private credit solutions across the continent.
Apera’s Strategic Position in the Lower Middle Market
Founded in 2016, Apera specialises in providing senior secured lending to private equity-backed companies in Western Europe. Operating from hubs in London, Germany, France, and Luxembourg, the firm has built a disciplined underwriting approach and solid sponsor relationships. Its recently closed €2.9 billion flagship fund exceeded fundraising targets, underscoring investor appetite for exposure to the European lower mid-market private credit space.
Leadership Comments on Strategic Alignment
Klaus Petersen, Apera’s Founding Partner, emphasised the alignment in vision with Franklin Templeton: “We share a performance-driven, responsible growth philosophy. With Franklin Templeton’s global reach, we can scale our strategy and enhance investor value.”
David Manlowe, CEO of Benefit Street Partners, noted: “Apera’s focus complements our offerings. Their expertise in Europe’s lower mid-market adds a new dimension to our platform.”
Franklin Templeton CEO Jenny Johnson added: “Acquiring Apera reflects our steadfast commitment to building a top-tier alternatives platform globally. We are excited to welcome their team.”
Completion Timeline and Regulatory Approval
The acquisition is subject to customary regulatory clearances and is expected to close in the third quarter of 2025.
